Kathrine Sofia Rallis, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Medical, Undergraduate | 6 | 2021 | 1068 | 1.980 |
Why?
|
| Students, Medical | 7 | 2021 | 1934 | 1.780 |
Why?
|
| Radiation Oncology | 2 | 2021 | 563 | 0.930 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 1896 | 0.640 |
Why?
|
| Education, Medical | 2 | 2020 | 1724 | 0.630 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 196 | 0.610 |
Why?
|
| Immunotherapy | 3 | 2021 | 4642 | 0.550 |
Why?
|
| Medical Oncology | 4 | 2021 | 2317 | 0.550 |
Why?
|
| Clinical Clerkship | 1 | 2020 | 564 | 0.460 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 10175 | 0.430 |
Why?
|
| Pandemics | 5 | 2021 | 8645 | 0.420 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3088 | 0.410 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3209 | 0.410 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1467 | 0.370 |
Why?
|
| Curriculum | 2 | 2021 | 3738 | 0.350 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2023 | 3164 | 0.330 |
Why?
|
| Telemedicine | 3 | 2021 | 3050 | 0.320 |
Why?
|
| Kidney Neoplasms | 2 | 2023 | 4250 | 0.300 |
Why?
|
| Neoplasms | 3 | 2021 | 22131 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 5672 | 0.210 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2023 | 120 | 0.200 |
Why?
|
| Ampulla of Vater | 1 | 2023 | 149 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2023 | 2020 | 0.180 |
Why?
|
| Internship and Residency | 1 | 2020 | 5878 | 0.170 |
Why?
|
| Lymphocyte Transfusion | 1 | 2021 | 232 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 218 | 0.170 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2021 | 880 | 0.160 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 339 | 0.160 |
Why?
|
| Competency-Based Education | 1 | 2020 | 222 | 0.160 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2022 | 384 | 0.160 |
Why?
|
| Social Responsibility | 1 | 2021 | 385 | 0.150 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 424 | 0.150 |
Why?
|
| MicroRNAs | 2 | 2023 | 3805 | 0.140 |
Why?
|
| Public Opinion | 1 | 2020 | 484 | 0.140 |
Why?
|
| Organ Specificity | 1 | 2021 | 1964 | 0.130 |
Why?
|
| Precancerous Conditions | 1 | 2022 | 980 | 0.130 |
Why?
|
| Canada | 1 | 2021 | 2118 | 0.120 |
Why?
|
| Mentors | 1 | 2020 | 661 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 955 | 0.120 |
Why?
|
| Humans | 21 | 2023 | 760617 | 0.120 |
Why?
|
| Schools, Medical | 1 | 2020 | 878 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 2546 | 0.100 |
Why?
|
| Biological Products | 1 | 2021 | 912 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2021 | 2331 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 1611 | 0.090 |
Why?
|
| Disease Management | 1 | 2021 | 2506 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8516 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 10754 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 3077 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2021 | 2948 | 0.070 |
Why?
|
| Palliative Care | 1 | 2020 | 3592 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3351 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 6340 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 26049 | 0.050 |
Why?
|
| Methylation | 1 | 2022 | 1077 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2023 | 509 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2021 | 203 | 0.040 |
Why?
|
| Access to Information | 1 | 2021 | 316 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 11106 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20556 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1700 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2023 | 1524 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2022 | 1117 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 858 | 0.030 |
Why?
|
| ROC Curve | 1 | 2023 | 3575 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2021 | 2567 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 704 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 846 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2021 | 64568 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2023 | 2048 | 0.030 |
Why?
|
| Income | 1 | 2021 | 1870 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 3492 | 0.020 |
Why?
|
| Histones | 1 | 2022 | 2577 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 2921 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3868 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 3196 | 0.020 |
Why?
|
| Female | 5 | 2023 | 392148 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 5672 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15251 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9277 | 0.010 |
Why?
|
| Phenotype | 1 | 2021 | 16571 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 5430 | 0.010 |
Why?
|
| Prognosis | 1 | 2023 | 29600 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23972 | 0.010 |
Why?
|
| Pregnancy | 1 | 2021 | 29868 | 0.010 |
Why?
|
| Male | 3 | 2023 | 360358 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 74115 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 59179 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2023 | 80566 | 0.010 |
Why?
|
| Aged | 1 | 2023 | 169042 | 0.010 |
Why?
|
| Middle Aged | 1 | 2023 | 220584 | 0.000 |
Why?
|
| Adult | 1 | 2021 | 220969 | 0.000 |
Why?
|